TL;DR
- FDA published a nationwide consumer-level recall of Lipofit Extreme Fat Burner 2.0 on August 31.
- FDA laboratory testing found undeclared fluoxetine in the AM tablets and 2,4-dinitrophenol (DNP) in the PM tablets.
- Fluoxetine is an active ingredient in FDA-approved prescription drugs.
- FDA describes DNP as a toxic substance illegally marketed for weight loss and not FDA-approved for any use.
- FDA says products containing fluoxetine and DNP cannot be marketed as dietary supplements and identifies Lipofit as an unapproved new drug.
- No known adverse events had been reported to the company at the time of the recall.
What Happened?
The recalled product is Lot 25M12F, expiration 09/2027. It was marketed directly to U.S. consumers through online sales.
FDA testing found different undeclared substances in the day and night tablets:
AM tablet → fluoxetine
PM tablet → DNP.
That instantly changes the product’s regulatory character.
This is not simply a labeling omission.
Why “Dietary Supplement” on the Label Does Not Decide Regulatory Status
A product does not become a lawful dietary supplement because the manufacturer prints those words on the bottle. FDA states that products containing fluoxetine and DNP cannot be marketed as dietary supplements.
Fluoxetine is a drug ingredient. DNP is not approved by FDA for any use and is described by FDA as a toxic substance that has been illegally marketed for weight loss. FDA therefore characterizes the product as an unapproved new drug for which safety and effectiveness have not been established.
That is the regulatory lesson worth emphasizing.
Product category follows composition, claims and law—not branding.
Why This Combination Is Particularly Concerning
The company/FDA posting describes potential adverse effects including serious cardiovascular and neurological consequences and dangerous elevation of body temperature.
Because the ingredients were undeclared, a consumer or healthcare professional might not know to consider:
- drug interactions;
- contraindications;
- serotonin-related effects;
- cardiac risk;
- DNP toxicity.
Hidden ingredients remove a critical risk-control layer: informed use.
The Supplier-Control Question
The public recall notice does not say how fluoxetine and DNP entered the product.
So it would be inappropriate to declare:
- supplier fraud;
- cross-contamination;
- intentional formulation;
- manufacturing mix-up
without evidence.
But other supplement manufacturers can still use the event to test their controls.
Ask:
- Do we verify raw-material identity?
- Do we qualify contract manufacturers?
- Are high-risk weight-loss/sexual-enhancement/bodybuilding categories subject to enhanced surveillance?
- Are unexpected chromatographic peaks investigated?
- Can supplier changes occur without Quality approval?
- Do we audit formulation and batch records against label claims?
The goal is not to guess this company’s root cause. It is to verify your system could detect a similar problem.
Why Online Distribution Matters
FDA says the product was sold directly to individual consumers online.
Digital sales can make unsafe products scale quickly across jurisdictions without a traditional retail gatekeeper.
That makes:
- customer traceability;
- rapid notification;
- transaction records;
- inventory quarantine
especially important during recalls.
What Supplement Companies Should Learn
High-risk categories deserve enhanced ingredient-authenticity controls.
A simple Certificate of Analysis from the supplier may be inadequate where economic incentives exist to add potent pharmacological substances.
Risk-based controls may include:
- identity testing;
- targeted screening;
- supplier audits;
- contract-manufacturer oversight;
- periodic independent testing;
- complaint surveillance.
The exact program should be proportionate to product risk.
Frequently Asked Questions
What did FDA find in Lipofit Extreme Fat Burner 2.0?
Fluoxetine in the AM tablets and 2,4-dinitrophenol in the PM tablets.
Is DNP approved for weight loss?
No. FDA says DNP is not approved for any use and has been illegally marketed for weight loss.
Can a supplement contain fluoxetine?
FDA states that products containing fluoxetine and DNP cannot be marketed as dietary supplements.
Were adverse events reported?
The company said it had received no known adverse-event reports related to the recall at the time of the announcement.
What should other manufacturers review?
Ingredient identity testing, supplier qualification, contract-manufacturer oversight and targeted screening for high-risk supplement categories.